PT - JOURNAL ARTICLE AU - Pascal Richette AU - Pierre Clerson AU - Laure Périssin AU - René-Marc Flipo AU - Thomas Bardin TI - Revisiting comorbidities in gout: a cluster analysis AID - 10.1136/annrheumdis-2013-203779 DP - 2015 Jan 01 TA - Annals of the Rheumatic Diseases PG - 142--147 VI - 74 IP - 1 4099 - http://ard.bmj.com/content/74/1/142.short 4100 - http://ard.bmj.com/content/74/1/142.full SO - Ann Rheum Dis2015 Jan 01; 74 AB - Objectives The reciprocal links between comorbidities and gout are complex. We used cluster analysis to attempt to identify different phenotypes on the basis of comorbidities in a large cohort of patients with gout.Methods This was a cross-sectional multicentre study of 2763 gout patients conducted from November 2010 to May 2011. Cluster analysis was conducted separately for variables and for observations in patients, measuring proximity between variables and identifying homogeneous subgroups of patients. Variables used in both analyses were hypertension, obesity, diabetes, dyslipidaemia, heart failure, coronary heart disease, renal failure, liver disorders and cancer.Results Comorbidities were common in this large cohort of patients with gout. Abdominal obesity, hypertension, metabolic syndrome and dyslipidaemia increased with gout duration, even after adjustment for age and sex. Five clusters (C1–C5) were found. Cluster C1 (n=332, 12%) consisted of patients with isolated gout and few comorbidities. In C2 (n=483, 17%), all patients were obese, with a high prevalence of hypertension. C3 (n=664, 24%) had the greatest proportion of patients with type 2 diabetes (75%). In C4 (n=782, 28%), almost all patients presented with dyslipidaemia (98%). Finally, C5 (n=502, 18%) consisted of almost all patients with a history of cardiovascular disease and renal failure, with a high rate of patients receiving diuretics.Conclusions Cluster analysis of comorbidities in gout allowed us to identify five different clinical phenotypes, which may reflect different pathophysiological processes in gout.